<DOC>
	<DOCNO>NCT02149888</DOCNO>
	<brief_summary>Canada continue see unrelenting stream new HIV diagnosis , disproportionate burden among gay , bisexual , MSM major center Toronto . Pre-exposure prophylaxis ( PrEP ) oral , daily tenofovir/emtricitabine ( TDF/FTC , TruvadaÂ® ) novel biomedical approach HIV prevention show iPrEx trial safe efficacious reduce HIV acquisition 44 % among MSM , provide comprehensive package HIV prevention intervention include counseling , testing/treatment sexually transmit infection ( STIs ) , condom . There widespread mobilization ass feasibility PrEP roll-out worldwide , urgent call 'demonstration project ' address real-world PrEP implementation issue . PREPARATORY-5 Canada 's first PrEP demonstration project , examine real-world PrEP implementation issue include acceptability , effectiveness , impact sexually transmitted infection , strategy support adherence outside clinical trial setting . The investigator also establish comprehensive community-based research program investigating role community-based organization PrEP implementation delivery .</brief_summary>
	<brief_title>PRe-Exposure Prophylaxis Acceptability &amp; Readiness Assessments Toronto gaY , Bisexual Other Men Who Have Sex With Men-5</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Selfidentified man sex men Age 18 year older Able communicate write oral english HIRIMSM score great equal 10 At least one selfreported unprotected receptive anal sex act precede 6 month Creatinine clearance great equal 60mL/min Modified Diet Renal Disease ( MDRD ) formula HIV uninfected screen use standard ELISA Western Blot test Clinical sign symptom suggestive HIV seroconversion illness within last 3 month opinion investigator Use pre postexposure prophylaxis within last 3 month Use concomitant nephrotoxic drug Use concomitant immune modulatory drug Hepatitis B surface antigen positivity Any condition concomitant medication portend increase risk osteoporosis Enrollment HIV prevention program trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Pre-Exposure Prophylaxis</keyword>
	<keyword>PrEP</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>